Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series

Ulriksdotter, Josefin LU orcid ; Svedman, Cecilia LU ; Bruze, Magnus LU ; Glimsjö, Jenny ; Källberg, Kajsa ; Sukakul, Thanisorn LU orcid and Mowitz, Martin LU (2020) In Contact Dermatitis 83(4). p.301-309
Abstract

Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a... (More)

Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
adhesive, allergic contact dermatitis, diabetes mellitus, FreeStyle Libre, glucose sensor, isobornyl acrylate, medical device, N,N-dimethylacrylamide
in
Contact Dermatitis
volume
83
issue
4
pages
9 pages
publisher
Wiley-Blackwell
external identifiers
  • pmid:32608015
  • scopus:85088638175
ISSN
0105-1873
DOI
10.1111/cod.13649
language
English
LU publication?
yes
id
6d3a8fb5-09a5-4da9-af88-14f9d719422a
date added to LUP
2020-09-30 15:40:50
date last changed
2025-10-18 05:36:34
@article{6d3a8fb5-09a5-4da9-af88-14f9d719422a,
  abstract     = {{<p>Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.</p>}},
  author       = {{Ulriksdotter, Josefin and Svedman, Cecilia and Bruze, Magnus and Glimsjö, Jenny and Källberg, Kajsa and Sukakul, Thanisorn and Mowitz, Martin}},
  issn         = {{0105-1873}},
  keywords     = {{adhesive; allergic contact dermatitis; diabetes mellitus; FreeStyle Libre; glucose sensor; isobornyl acrylate; medical device; N,N-dimethylacrylamide}},
  language     = {{eng}},
  month        = {{10}},
  number       = {{4}},
  pages        = {{301--309}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Contact Dermatitis}},
  title        = {{Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series}},
  url          = {{http://dx.doi.org/10.1111/cod.13649}},
  doi          = {{10.1111/cod.13649}},
  volume       = {{83}},
  year         = {{2020}},
}